Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radium-223 dichloride + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy of **radium-223 dichloride**, an alpha-emitting radiopharmaceutical, and **pembrolizumab**, a programmed death-1 (PD-1) immune checkpoint inhibitor monoclonal antibody. Radium-223 selectively targets bone metastases with high-energy, short-range alpha-particles causing double-stranded DNA breaks in adjacent tumor cells, approved for metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases and no known visceral metastatic disease. Pembrolizumab blocks PD-1, restoring T-cell–mediated antitumor immunity. The combination has been investigated in phase II trials for mCRPC to bone, with studies showing that pembrolizumab addition does not significantly enhance immune infiltration or clinical outcomes beyond radium-223 alone, but the regimen is generally well tolerated[1][3][5][7][9].
- Brand names
- KeytrudaXofigo
- Other names
- radium Ra 223 dichloride + pembrolizumabRa-223 + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on radium-223 dichloride + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radium-223 dichloride + pembrolizumab.